Selank (AC-Selank-NH2) | Pen

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin and explored as a regulatory neuropeptide in stress-response and cognitive-stability research. Across clinical, preclinical, and in vitro work, it has been studied for its relationship to GABAergic tone, monoaminergic signaling context, and neuroimmune marker patterns under stress-relevant conditions. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.

Supports

1. Stress-response signaling context tracked through inhibitory neurotransmission (GABA-related) readouts in models.
2. Monoaminergic balance frameworks associated with serotonin/dopamine signaling markers.
3. Cognitive stability endpoints monitored under stress-exposure paradigms.
4. Neuroimmune interaction context assessed via cytokine and inflammation-related gene-expression patterns.
5. Neurotrophic and synaptic-function research readouts in controlled experimental systems.

Description

Selank is a tuftsin-derived synthetic heptapeptide developed within the broader class of glyproline regulatory peptides. It is widely referenced in neurobehavioral research because its reported profile differs from classical sedative anxiolytics: rather than acting as a direct GABA-A receptor agonist, Selank is commonly described as a modulator of inhibitory signaling tone and broader neurotransmission-related pathways in model systems.

In controlled research settings, Selank has been evaluated in stress-exposure paradigms and cognitive-performance contexts where behavioral endpoints are paired with molecular readouts (e.g., neurotransmission-related gene expression, cytokine markers, and neurotrophic-factor signaling context). Reported observations are model- and protocol-dependent and should be interpreted within each study’s design and endpoints.

Selank is presented here for controlled research and educational context only. It is not marketed as an approved therapeutic product, and outcomes can vary substantially by model, endpoints, and study design.

Clinical Status

Selank has published human research in anxiety-related study contexts as well as extensive preclinical and in vitro investigation of neurotransmission and neuroimmune endpoints. It is not presented here as an approved therapeutic product, and interpretation should remain study-specific and endpoint-driven.

Evidence type:
Human RCT ✔ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

Mechanistic narratives around Selank commonly emphasize modulation of inhibitory neurotransmission and downstream stress-response signaling. Transcriptomic and molecular studies report changes in gene-expression patterns related to neurotransmission, with particular focus on GABAergic system context and its intersection with stress-related pathways. Experimental work also discusses monoaminergic signaling markers (serotonin/dopamine context) as part of broader regulation of emotional and cognitive stability readouts.

Beyond neurotransmission, Selank has been investigated for neuroimmune interactions, including cytokine-related readouts and inflammation-associated gene expression under stress conditions. Some electrophysiology studies also explore effects on inhibitory synaptic transmission in hippocampal systems, positioning Selank within synaptic-function research frameworks.

Benefits

• Modulation Of GABAergic Signaling:
  Selank has been studied for its ability to influence GABA turnover without directly binding to GABA-A receptors. Research indicates normalization of inhibitory neurotransmission in stress-exposed animal models. Unlike benzodiazepines, Selank does not produce strong sedative or motor-impairing effects in experimental settings. Behavioral studies demonstrate reduced anxiety markers with preserved cognitive function. Evidence type: Human clinical studies ✔ | Animal ▣.
• Serotonin And Dopamine Regulation:
  Preclinical and clinical data suggest modulation of monoamine systems, particularly serotonin and dopamine pathways. Research indicates improved neurotransmitter balance under stress conditions. Laboratory findings demonstrate altered transporter expression and receptor sensitivity. These mechanisms contribute to emotional stability and cognitive clarity research contexts.
• Anxiety Model Performance Improvements:
  Clinical studies in anxiety-related research populations demonstrate measurable reductions in anxiety scoring scales. Behavioral assessments show improved emotional regulation without cognitive dulling. Comparative studies suggest preservation of attentional performance during administration.
• Stress-Response Regulation:
  Animal models indicate ↓ stress-induced corticosterone elevation following Selank exposure. Research suggests modulation of hypothalamic-pituitary-adrenal axis signaling. These effects contribute to stabilized physiological stress responses in experimental settings.
• Neuroimmune Interaction Modulation:
  Gene expression studies demonstrate influence on inflammatory cytokine regulation within neural tissue. Research indicates potential interplay between immune signaling and neural modulation pathways. This dual regulatory profile distinguishes Selank from purely neurotransmitter-targeted compounds.
• Cognitive Stability Under Stress Conditions:
  Selank has been evaluated in cognitive testing models under acute stress exposure. Research demonstrates preservation of memory recall and executive performance compared to controls. Mechanistic hypotheses involve monoaminergic stabilization and reduced stress hormone signaling.
• Non-Sedative Regulatory Profile:
  Unlike classical anxiolytic agents, Selank does not produce significant sedation in controlled research models. Motor coordination and reaction time metrics remain largely preserved. This characteristic supports its positioning in cognitive-focused anxiety research.
• High Bioavailability Through Subcutaneous Administration:
  Provided in a stabilized pre-mixed injection pen for SubQ administration, ensuring consistent systemic exposure in research protocols. Subcutaneous delivery supports reliable absorption and simplified laboratory handling. Each unit is freshly prepared and intended strictly for research use only.
• 
  

Research Data

Stack Suggestions

In extended experimental designs, Selank is sometimes paired with:

• Semax (neurotrophic and cognitive-endpoint frameworks, where applicable)
• DSIP (sleep/stress-endpoint study designs, depending on protocol)
• NAD+ (bioenergetic and stress-resilience marker panels in broader neurobiology studies)

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

In research contexts, tolerability notes for Selank are generally described as mild and model-dependent. Where administered, observations may include transient local sensitivity or short-lived systemic effects. These notes are provided for general context only; they do not constitute medical guidance.

Injection-site sensitivity: Temporary redness, swelling, or discomfort has been reported in some settings.
Headache or fatigue: Transient effects have been noted anecdotally in certain protocols.
Dizziness or nausea: Occasional reports during early exposure windows in some settings.
Sensitivity reactions: Rare hypersensitivity-like responses are possible and warrant caution.

Scientific References

• Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia — Human clinical study
• The Molecular Aspects of Heptapeptide Selank Biological Activity — Review
• Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission — Animal / gene expression
• Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission (full text) — Animal / gene expression (PMC)
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission — Transcriptomic / mechanistic context
• The Influence of Selank on the Level of Cytokines Under Social Stress Conditions — Animal / cytokines
• Peptide Selank Enhances the Effect of Diazepam in Unpredictable Chronic Mild Stress Conditions — Animal / stress model
• Peptide Selank Enhances the Effect of Diazepam in Unpredictable Chronic Mild Stress Conditions (full article page) — Animal / stress model
• Peptidergic modulation of the hippocampus synaptic activity — Electrophysiology (inhibitory synaptic transmission)
• Expression of inflammation-related genes in mouse spleen after administration of Selank and its fragments — Animal / gene expression

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.